A number of 7-alkyl 4-aminopyrrolo[2,3-glpyrimidine derivatives related to toyocamycin, sangivamycin and thiosangivamycin have been prepared and tested for their activity against human cytomegalovirus (HCMV). Only the thioamide substituted derivatives demonstrated biological activity. but are highly toxic to mammalian cells. -9 12 Both toyocamycin and sangivamycin are phosphorylated by celfular adenosine kinase which ul~mately leads to their toxicity in uninfested cells.13 In previous studies of sugar modified analogs of 1,2 and 3,tr-l2.14-rs t i was reported that acyclic analogs of 3 possesssed good activity against HCMV coupled with a significant reduction in cytotoxicity;lr, 14-rs e.g., 4-amino-7-[(2-
The clinical use of these compounds is limited because of host toxicity. s-6 In addition, there have been recent report@ that strains of HCMV resistant to both drugs are emerging.
Hence, there is a continued need to develop compounds which may circumvent the problems associated with the use of DHPG and PFA to treat HCMV infections.
The naturally occurring pyrrolo [2,3-d] pyrimidine nucleosides toyocamycin (I), sangivamycin (2) and a structurally related analog, thiosangivamycin (3), possess significant activity against HCMVg-lo but are highly toxic to mammalian cells. -9 12 Both toyocamycin and sangivamycin are phosphorylated by celfular adenosine kinase which ul~mately leads to their toxicity in uninfested cells. 13 In previous studies of sugar modified analogs of 1,2 and 3,tr-l2.14-rs t i was reported that acyclic analogs of 3 possesssed good activity against HCMV coupled with a significant reduction in cytotoxicity;lr, 14-rs e.g., 4-amino-7-[(2-* Portions of this study were presented at the 204th American Chemical Society National Meeting (Medi # 1811, August 1992, Washington D. C.
T. E. RENAU et ul. cannot be phosphorylated.
In the present report, we describe the synthesis, antiviral activity and cytotoxicity of a number of model compounds.
Scheme I illustrates the synthetic route we used to prepare the non-nucleoside analogsz2 Compounds 7a
and 7b were prepared m a similar manner to that reported for 4 14 from 2-amino-5-bromo-3,4-dicyanopyrrole base, and the thiosangivamycin analogs (10 a-c) were also prepared from the appropriate nitrile (8) in methanolic sodium sulfide in a sealed vessel at 95" C in 80-9.5% yields.
Compounds 8a-c, 9a-c and IOa-c were evaluated for activity against HCMV by a plaque reduction assay9 in human foreskin fibroblasts (HFF cells), and the cytotoxicity of each compound in uninfected cells was determined by examining the effects on the growth of KB cells. 24 The results are presented in Table I .
Antiviral and cytoxicity data for the ribosyl, hydroxyethoxymethyl and dihydroxypropoxymethyl substituted pyrrolopyrimidines are presented for comparison.
The data confirm that the major factor required for the antiviral activity of these 7-substituted 4-aminopyrrolo- [2,3_d] pyrimidines is the thioamide moiety at the 5-position (Rl), and that the hydroxyl group of 3 or 4 1s not necessarily required for the compound to have activity against HCMV. As with the acyclic analogs, It,15 the non-nucleoside analogs of toyocamycin (Sax) and sangivamycm (9a-c) were non-toxic and relatively inactive against HCMV. In general, the thioamides were more toxic than the carboxamides which, in turn, were more toxic than the corresponding nitriles. Although the potency of compounds lOa-c against HCMV is greater than that of 4, the toxicity in uninfected cells also was greater. Therefore, the selectivity index for analogs lOa-c remain essentially the same when compared to that of the parent compound 4 (therapeutic ratios of 9-14 vs 13, respectively). The separation of cytotoxicity from antiviral activity, though, is greater for compounds lOa-c when compared to that of thiosangivamycm (3), tndicating viral selectivity.
In summary, the design, synthesis and antiviral evaluation of several non-nucleoside pyrrolo- [2, [3] [4] [5] [6] [7] [8] pyrimidines was examined. This study was initiated to investigate the possibility that a side chain hydroxyl group of analogs with known activity against HCMV, such as compounds 3 or 4, may not be required for biological activity. The data herein suggest that the thioamide moiety provides antiviral activity without the requirement for phosphorylation of a side chain hydroxyl group. Since the activity of these compounds is mediated via a unique mechanism, biological studies to elucidate the mechanism of action are underway. We are expanding our studies with this class of compounds by making several selective alkyl and aryl substitutions at the 7-position of the base as well as examining modifications at other sites on the heterocycle with the initial goal of increasing the therapeutic index.
